VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 87 filers reported holding VAXCYTE INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,878,859 | -1.6% | 409,550 | -3.7% | 0.00% | 0.0% |
| Q2 2023 | $21,228,995 | +232.0% | 425,090 | +149.1% | 0.00% | +100.0% |
| Q1 2023 | $6,394,949 | -20.7% | 170,623 | +1.5% | 0.00% | 0.0% |
| Q4 2022 | $8,061,114 | +689.5% | 168,115 | +295.3% | 0.00% | – |
| Q3 2022 | $1,021,000 | -65.9% | 42,533 | -69.1% | 0.00% | – |
| Q2 2022 | $2,996,000 | +39.5% | 137,671 | +54.8% | 0.00% | – |
| Q1 2022 | $2,148,000 | +56.1% | 88,931 | +53.7% | 0.00% | – |
| Q4 2021 | $1,376,000 | +42.4% | 57,843 | +51.9% | 0.00% | – |
| Q3 2021 | $966,000 | +115.1% | 38,076 | +91.6% | 0.00% | – |
| Q2 2021 | $449,000 | +140.1% | 19,876 | +109.9% | 0.00% | – |
| Q1 2021 | $187,000 | -48.1% | 9,471 | -30.1% | 0.00% | – |
| Q4 2020 | $360,000 | +146.6% | 13,559 | +358.2% | 0.00% | – |
| Q3 2020 | $146,000 | +4766.7% | 2,959 | +2859.0% | 0.00% | – |
| Q2 2020 | $3,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $82,124,000 | 28.36% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $37,277,000 | 21.71% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,405,421 | $27,757,000 | 8.90% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $45,614,000 | 3.66% |
| RA Capital Management | 3,865,808 | $76,350,000 | 1.15% |
| TPG Group Holdings (SBS) Advisors, Inc. | 4,558,475 | $90,030,000 | 1.05% |
| Soleus Capital Management, L.P. | 293,650 | $5,800,000 | 1.04% |
| Opaleye Management Inc. | 357,800 | $7,067,000 | 1.04% |
| SABBY MANAGEMENT, LLC | 178,992 | $3,535,000 | 0.69% |
| Penn Mutual Asset Management, LLC | 22,227 | $439,000 | 0.50% |